Comparative Pharmacology
Head-to-head clinical analysis: BRONKAID MIST versus FORADIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKAID MIST versus FORADIL.
BRONKAID MIST vs FORADIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine, the active ingredient, is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Beta-2 receptor activation in bronchial smooth muscle causes bronchodilation. Alpha receptor activation causes vasoconstriction, reducing mucosal edema.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
2 inhalations (200 mcg per inhalation) every 4 hours as needed for bronchospasm. Maximum 12 inhalations in 24 hours.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours; clinical context: shorter half-life in children, prolonged in hepatic impairment; requires frequent dosing
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Renal: 40-70% unchanged; fecal: minor (biliary) <5%
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator